Rituximab as a first-line preventive treatment in pediatric NMOSDs

Giulia Longoni; Brenda Banwell; Massimo Filippi; E. Ann Yeh

doi:10.1212/nxi.0000000000000046

Related publications

Article2014

Rituximab Therapy As A First-Line Immunosuppressive Treatment In Children With Neuromyelitis Optica Spectrum Disorder: A Single-Center Experience. (P7.325)

Giulia Longoni, Brenda Banwell, Massimo Filippi, E. Ann Yeh

Article2002

Treatment of Waldenström’s Macroglobulinemia With Rituximab

Meletios A Dimopoulos, Constantinos Zervas, Athanassios Zomas, Christos Kiamouris, Nora Viniou, Vassiliki Grigoraki, Christos Karkantaris, Chrisanthi Mitsouli, Dimitra Gika, John Christakis, Nikolaos Anagnostopoulos

Article2004

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A Dimopoulos, Maria Christina Kyrtsonis, Constantinos Tsatalas, Garyfallia Kokkini, Panagiotis Repoussis, Athanasios Zomas, Argiris Symeonidis, Evridiki Michali, Athanasios K. Anagnostopoulos, Nikolaos Anagnostopoulos, T. Economopoulos, Gerasimos Pangalis

Article2014

Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?

Paolo Cravedi, Giuseppe Remuzzi, Piero Ruggenenti

Article2006

Treatment of Low-Grade Non-Hodgkin Lymphomas with Fludarabine and Mitoxantrone Followed by Rituximab Maintenance: Results of a Phase II Study.

Amanda Psyrri, Meletios A Dimopoulos, George Fountzilas, Constantinos Tsatalas, Αchilles Anagnostopoulos, Sotirios G. Papageorgiou, Nikolaos I. Xiros, Theofanis Economopoulos